tirzepatide heart failure trial Lilly says weight loss drug cuts risk by 38% in Has Tirzepatide Scaled the HFpEF/Obesity

The D-Retro-Inverso modification provides protease resistance

1,6 Despite normal secretion of GLP-1 and GIP, the incretin effect is reduced or absent in people with type 2 diabetes, with the insulin-stimulating effect of GIP being more impaired when compared to GLP-1

Average Weight Loss Results Clinical data shows that patients can lose between 10% to 22% of their total body weight over 6 to 12 months

GHK-CU doesn't simply "improve" skin

What stands out to me is not how few new launches there arebut how tightly constrained innovation has become

An endocrinologist or a general practitioner can review your symptoms and medication regimen